GlassScriptPhysician profile
Nelson C Cabagnot
NPI 1720116528
$1,142.72
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2021: $17.76 · 2022: $23.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $166.44 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $158.85 | 2019 | |
| Merck Sharp & Dohme LLC | $124.86 | 2019 | |
| Gilead Sciences, INC. | $93.60 | 2019 | |
| Pfizer INC. | $62.80 | 2019-2021 | |
| Allergan, INC. | $57.65 | 2019 | |
| Amarin Pharma, INC. | $43.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $43.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.66 | 2019 | |
| Glaxosmithkline, LLC. | $39.19 | 2019 | |
| Lilly USA, LLC | $36.87 | 2019 | |
| Horizon Therapeutics Plc | $34.02 | 2019 | |
| Abbvie INC. | $23.93 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.53 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17.53 | 2019 | |
| Sanofi Pasteur INC. | $14.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Cabagnot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.